SEC Form 4 · accession 0001209191-16-149227
Sarepta Therapeutics, Inc. · SRPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Edward M. Kaye M.D.
Officer — President, CEO & CMO · Director
Period of report
Nov 9, 2016
Accepted (ET)
Nov 10, 2016 · 8:19 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000873303
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 9, 2016 | M | 3,000 | $8.28 | A | 75,635 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock Option (right to buy)F1 | $8.28 | Nov 9, 2016 | M | 3,000 | D | — | Jun 20, 2021 | Common Stock | 3,000 | 45,309 | D |
Explanation of responses
- F1This option became exercisable at the rate of 25% of the shares on June 20, 2012 and 1/48th of the total granted shares on each monthly anniversary thereafter, such that the option became fully exercisable on June 20, 2015.